(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NNMZSMRB'); SEO title 01 EN
Media center
Career

Global

French

United Kingdom

Contact US
Media center Career

Press release

July 12, 2022

|

Marseille, France and Collegeville, PA, USA

Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection

Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that it has received FDA New Drug Approval for the marketing of BLUDIGO™, its indigo carmine injectable (Indigotindisulfonate Sodium) drug product. BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults, following urological and gynecological open, robotic or endoscopic surgical procedures.

Press release

July 12, 2022

|

Marseille, France and Collegeville, PA, USA